# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-08-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review: A1c, lipids, walking program, eye treatment, and foot care. **S**

## History of present illness

Ms. Fitzgerald returns three months after her first visit, after a two-week run of concerts. She completed ten weeks of the supervised exercise program and walked to the home plan on tour; she can now walk about three blocks before calf pain, and the pain eases faster. She has had three right-eye injections, and her right eye is clearer. The podiatrist pared her calluses and she now performs in low-heeled custom stage shoes. Her glucose monitor shows time in range 66% and time below 70 mg/dL 0.8%, with no reading below 54 mg/dL; she ate before every late show. She has had no bleeding on rivaroxaban and aspirin. Her hepatitis C screening test was negative. She would like to know whether anything else can help her legs and her glucose. **S**

| Element | Detail |
|---|---|
| Glucose | Time in range 66%; time below 70 mg/dL 0.8%; none below 54 |
| Walking | About three blocks, from one and a half |
| Eye treatment | Three right-eye injections; vision clearer |
| Feet | Calluses pared; low-heeled stage shoes |
| Bleeding | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf pain after about three blocks; no chest pain or rest pain |
| Eyes | Positive | Right-eye blur better |
| Hematologic | Negative | No bruising, nosebleeds, or blood in the urine or stool |
| Integumentary | Negative | No foot sores |

4 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**
- Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg **S**
- Semaglutide 0.25 mg under the skin once weekly for four weeks **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/68 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 82.1 kg; BMI 30.2 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 7.6% (high); Sodium: 140 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 0.96 mg/dL; eGFR: 64 mL/min/1.73 m²; Total cholesterol: 128 mg/dL; LDL cholesterol: 64 mg/dL; HDL cholesterol: 46 mg/dL (low); Triglycerides: 112 mg/dL; Best-corrected visual acuity, right eye (ETDRS letters): 71 (low); Best-corrected visual acuity, left eye (ETDRS letters): 81. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.6% (high) at baseline, 7.6% (high) at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- eGFR: 67 mL/min/1.73 m² at baseline, 64 mL/min/1.73 m² at this visit **S**
- Total cholesterol: 164 mg/dL at baseline, 128 mg/dL at this visit **S**
- LDL cholesterol: 92 mg/dL at baseline, 64 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL (low) at baseline, 46 mg/dL (low) at this visit **S**
- Triglycerides: 140 mg/dL at baseline, 112 mg/dL at this visit **S**
- Best-corrected visual acuity, right eye (ETDRS letters): 64 (low) at baseline, 71 (low) at this visit **S**
- Best-corrected visual acuity, left eye (ETDRS letters): 81 at baseline, 81 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 82.1 kg, BMI 30.2; blood pressure 122/68, pulse 62 |
| Feet | Skin intact; small calluses; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; shoes fit well |
| Eyes | Best-corrected acuity 71 letters right and 81 letters left |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes with peripheral artery disease** (E11.51). A1c 7.6%, from 8.6%, without level 2 lows; still just above her goal below 7.5%. Walking distance has doubled with supervised exercise. With coronary and peripheral artery disease, a GLP-1 receptor agonist adds cardiovascular protection, and in people with peripheral artery disease and type 2 diabetes semaglutide has increased walking distance. Because a fast fall in glucose can briefly worsen retinopathy, the retina clinic was told before the start and the dose will rise slowly. Creatinine 0.96 mg/dL and eGFR 64, a small expected change on empagliflozin; potassium 4.6 mmol/L. **S**
   - Start semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly.
   - Eat smaller meals and stop eating when full; call for persistent vomiting or abdominal pain.
   - Continue glargine 24 units; lower it if fasting readings fall below 90 mg/dL.
   - Finish the twelve weeks of supervised exercise, then walk at least three times a week.
2. **Coronary artery disease after bypass surgery** (I25.10). LDL 64 mg/dL on atorvastatin 80 mg, above the goal below 55 mg/dL; HDL 46 and triglycerides 112 mg/dL. No angina. **S**
   - Add ezetimibe 10 mg daily.
   - Lipid panel in 4 to 12 weeks.
3. **Diabetic macular edema, right eye** (E11.3311). Acuity 71 letters, from 64, after three injections; the retina clinic will now lengthen the interval. **S**
   - Continue retina-clinic treatment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Completed today | 7.6%, from 8.6% |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 66%; time below 70 mg/dL 0.8%; none below 54 mg/dL |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No level 2 or 3 lows; ate before every late show; glucagon unused |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No genital infection; no dizziness on stage |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Completed today | Creatinine 0.96 mg/dL, eGFR 64, potassium 4.6, sodium 140 mmol/L |
| Laboratory | Urine albumin-creatinine ratio | Yearly | Up to date | 18 mg/g at intake |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Deferred | Due 4 to 12 weeks after atorvastatin was raised; drawn today at 13 weeks, one week late, because she was on tour. LDL 64 mg/dL, above goal; no harm from the one-week delay. Corrective action: lipid tests after any change are booked before she leaves on tour |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; protective sensation intact; podiatry seen in June, next visit in September |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Up to date | Repeat with duplex at the six-month vascular review |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | About three blocks before calf pain, from one and a half |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Completed today | Ten of twelve weeks done; home plan followed on tour |
| Imaging | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Completed today | Acuity 71 letters right and 81 left; three injections; retina clinic told about semaglutide |
| Examination | Blood pressure | Every visit | Completed today | 122/68 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 82.1 kg, down 1.9 kg |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | No bleeding |
| Medication safety | Semaglutide tolerance: nausea, appetite, and dose step | At the start and each dose step | Completed today | Starting today; nausea and dose steps explained |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Semaglutide cost checked with her Part D plan; next visit set before the autumn tour |

## Goal progress

- No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months. In progress; target 2026-10-26. **S**
- A1c below 7.5% by six months. In progress; target 2026-10-26. **S**
- LDL cholesterol below 55 mg/dL by six months. In progress; target 2026-10-26. **S**
- Walk at least four blocks without stopping by six months. In progress; target 2026-10-26. **S**
- No foot ulcer, and protective footwear on and off stage, through six months. In progress; target 2026-10-26. **S**

## Medication changes

- Started: Semaglutide 0.25 mg under the skin once weekly for four weeks **S**
- Started: Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026), Aether Forge
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025), The Lancet (Bonaca MP, et al.)

## Follow-up

- Semaglutide dose step in four weeks, by video visit if she is touring. Podiatry in September. Review in eleven weeks with A1c, lipids, and kidney tests; zoster vaccine dose 1 at that visit. **S**
- Next scheduled visit 2026-10-26: five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up. **S**
